nodes	percent_of_prediction	percent_of_DWPC	metapath
Medroxyprogesterone Acetate—Henoch-Schonlein purpura—Hydrochlorothiazide—nephrolithiasis	0.0573	0.0655	CcSEcCtD
Medroxyprogesterone Acetate—Leg pain—Hydrochlorothiazide—nephrolithiasis	0.0282	0.0322	CcSEcCtD
Medroxyprogesterone Acetate—Joint swelling—Hydrochlorothiazide—nephrolithiasis	0.0265	0.0303	CcSEcCtD
Medroxyprogesterone Acetate—Nephritis interstitial—Hydrochlorothiazide—nephrolithiasis	0.0193	0.022	CcSEcCtD
Medroxyprogesterone Acetate—Heartburn—Hydrochlorothiazide—nephrolithiasis	0.0189	0.0216	CcSEcCtD
Medroxyprogesterone Acetate—Tubulointerstitial nephritis—Hydrochlorothiazide—nephrolithiasis	0.017	0.0194	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—urine—nephrolithiasis	0.0166	0.133	CbGeAlD
Medroxyprogesterone Acetate—CYP2C9—urine—nephrolithiasis	0.0165	0.132	CbGeAlD
Medroxyprogesterone Acetate—Glycosuria—Hydrochlorothiazide—nephrolithiasis	0.0161	0.0184	CcSEcCtD
Medroxyprogesterone Acetate—Jaundice cholestatic—Hydrochlorothiazide—nephrolithiasis	0.0148	0.0169	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.0132	0.0151	CcSEcCtD
Medroxyprogesterone Acetate—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.0128	0.0146	CcSEcCtD
Medroxyprogesterone Acetate—CYP3A4—urine—nephrolithiasis	0.0126	0.1	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—nephron tubule—nephrolithiasis	0.0115	0.0913	CbGeAlD
Medroxyprogesterone Acetate—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.0109	0.0124	CcSEcCtD
Medroxyprogesterone Acetate—Swelling—Hydrochlorothiazide—nephrolithiasis	0.0107	0.0122	CcSEcCtD
Medroxyprogesterone Acetate—Haemolytic anaemia—Hydrochlorothiazide—nephrolithiasis	0.0105	0.012	CcSEcCtD
Medroxyprogesterone Acetate—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.0102	0.0116	CcSEcCtD
Medroxyprogesterone Acetate—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.0101	0.0115	CcSEcCtD
Medroxyprogesterone Acetate—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.0101	0.0115	CcSEcCtD
Medroxyprogesterone Acetate—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.01	0.0114	CcSEcCtD
Medroxyprogesterone Acetate—Visual disturbance—Hydrochlorothiazide—nephrolithiasis	0.00997	0.0114	CcSEcCtD
Medroxyprogesterone Acetate—Thirst—Hydrochlorothiazide—nephrolithiasis	0.00992	0.0113	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—cortex of kidney—nephrolithiasis	0.0098	0.0782	CbGeAlD
Medroxyprogesterone Acetate—Purpura—Hydrochlorothiazide—nephrolithiasis	0.0098	0.0112	CcSEcCtD
Medroxyprogesterone Acetate—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.00944	0.0108	CcSEcCtD
Medroxyprogesterone Acetate—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.00937	0.0107	CcSEcCtD
Medroxyprogesterone Acetate—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.0093	0.0106	CcSEcCtD
Medroxyprogesterone Acetate—Migraine—Hydrochlorothiazide—nephrolithiasis	0.0093	0.0106	CcSEcCtD
Medroxyprogesterone Acetate—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.00912	0.0104	CcSEcCtD
Medroxyprogesterone Acetate—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.00895	0.0102	CcSEcCtD
Medroxyprogesterone Acetate—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.00888	0.0102	CcSEcCtD
Medroxyprogesterone Acetate—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.00885	0.0101	CcSEcCtD
Medroxyprogesterone Acetate—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.00866	0.0099	CcSEcCtD
Medroxyprogesterone Acetate—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.00863	0.00986	CcSEcCtD
Medroxyprogesterone Acetate—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.0086	0.00983	CcSEcCtD
Medroxyprogesterone Acetate—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.00853	0.00976	CcSEcCtD
Medroxyprogesterone Acetate—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.0085	0.00972	CcSEcCtD
Medroxyprogesterone Acetate—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00833	0.00952	CcSEcCtD
Medroxyprogesterone Acetate—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.00833	0.00952	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.00822	0.0094	CcSEcCtD
Medroxyprogesterone Acetate—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.00816	0.00933	CcSEcCtD
Medroxyprogesterone Acetate—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00816	0.00933	CcSEcCtD
Medroxyprogesterone Acetate—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00763	0.00873	CcSEcCtD
Medroxyprogesterone Acetate—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00759	0.00867	CcSEcCtD
Medroxyprogesterone Acetate—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00754	0.00862	CcSEcCtD
Medroxyprogesterone Acetate—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.00743	0.00849	CcSEcCtD
Medroxyprogesterone Acetate—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00736	0.00842	CcSEcCtD
Medroxyprogesterone Acetate—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00717	0.0082	CcSEcCtD
Medroxyprogesterone Acetate—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.00713	0.00816	CcSEcCtD
Medroxyprogesterone Acetate—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00713	0.00816	CcSEcCtD
Medroxyprogesterone Acetate—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00709	0.00811	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00707	0.00809	CcSEcCtD
Medroxyprogesterone Acetate—Sweating—Hydrochlorothiazide—nephrolithiasis	0.00698	0.00798	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00686	0.00785	CcSEcCtD
Medroxyprogesterone Acetate—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00683	0.00781	CcSEcCtD
Medroxyprogesterone Acetate—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00665	0.00761	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.00653	0.00747	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00648	0.00741	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00644	0.00736	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.0063	0.0072	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00618	0.00706	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00609	0.00697	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00577	0.0066	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Hydrochlorothiazide—nephrolithiasis	0.00569	0.0065	CcSEcCtD
Medroxyprogesterone Acetate—AR—renal system—nephrolithiasis	0.00562	0.0448	CbGeAlD
Medroxyprogesterone Acetate—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.0056	0.00641	CcSEcCtD
Medroxyprogesterone Acetate—Tension—Hydrochlorothiazide—nephrolithiasis	0.00558	0.00638	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00557	0.00637	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00552	0.00632	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—renal system—nephrolithiasis	0.00551	0.044	CbGeAlD
Medroxyprogesterone Acetate—Back pain—Hydrochlorothiazide—nephrolithiasis	0.0055	0.00629	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00547	0.00625	CcSEcCtD
Medroxyprogesterone Acetate—AR—kidney—nephrolithiasis	0.00543	0.0433	CbGeAlD
Medroxyprogesterone Acetate—ESR1—kidney—nephrolithiasis	0.00533	0.0425	CbGeAlD
Medroxyprogesterone Acetate—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00533	0.00609	CcSEcCtD
Medroxyprogesterone Acetate—AR—cortex of kidney—nephrolithiasis	0.00529	0.0422	CbGeAlD
Medroxyprogesterone Acetate—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00528	0.00603	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00526	0.00601	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00523	0.00598	CcSEcCtD
Medroxyprogesterone Acetate—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.0052	0.00594	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00513	0.00586	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00511	0.00584	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Hydrochlorothiazide—nephrolithiasis	0.0051	0.00583	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00503	0.00575	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.005	0.00572	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00484	0.00554	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00484	0.00554	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00484	0.00554	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00483	0.00552	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00478	0.00547	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00474	0.00541	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00468	0.00535	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00464	0.00531	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00464	0.00531	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Hydrochlorothiazide—nephrolithiasis	0.00457	0.00522	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00454	0.0052	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—renal system—nephrolithiasis	0.00454	0.0362	CbGeAlD
Medroxyprogesterone Acetate—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00453	0.00518	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00449	0.00513	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—nephron tubule—nephrolithiasis	0.00447	0.0357	CbGeAlD
Medroxyprogesterone Acetate—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00442	0.00506	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—kidney—nephrolithiasis	0.00439	0.035	CbGeAlD
Medroxyprogesterone Acetate—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00434	0.00496	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00423	0.00484	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.0042	0.0048	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00417	0.00477	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00414	0.00473	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00413	0.00472	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00409	0.00467	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—renal system—nephrolithiasis	0.00407	0.0324	CbGeAlD
Medroxyprogesterone Acetate—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00404	0.00461	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.004	0.00458	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00397	0.00454	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—kidney—nephrolithiasis	0.00393	0.0314	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—cortex of kidney—nephrolithiasis	0.00383	0.0305	CbGeAlD
Medroxyprogesterone Acetate—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00383	0.00437	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.0038	0.00434	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00369	0.00422	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00367	0.0042	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00367	0.0042	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00342	0.00391	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00333	0.00381	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00328	0.00376	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00318	0.00363	CcSEcCtD
Medroxyprogesterone Acetate—CYP3A4—renal system—nephrolithiasis	0.00308	0.0245	CbGeAlD
Medroxyprogesterone Acetate—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00307	0.00351	CcSEcCtD
Medroxyprogesterone Acetate—CYP3A4—kidney—nephrolithiasis	0.00297	0.0237	CbGeAlD
Medroxyprogesterone Acetate—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00295	0.00337	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Hydrochlorothiazide—nephrolithiasis	0.00293	0.00335	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00292	0.00334	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Hydrochlorothiazide—nephrolithiasis	0.00291	0.00332	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00276	0.00315	CcSEcCtD
